Candidiasis Market to Surpass US$ 1,307.2 Million by 2026

Global Candidiasis Market, by Drug Class (Azoles, Echinocandins, Polyenes, and Flucytosine), by Type (Candida Infections of the Mouth, Throat, and Esophagus, Vaginal Candidiasis, and Invasive/Systemic Candidiasis), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 873.8 million in 2017, and is projected to exhibit a CAGR of 4.6% over the forecast period (2018–2026), as highlighted in a new report published by CMI.

Increasing adoption of inorganic growth strategies such as mergers and acquisitions for the development of novel drugs by market players is expected to propel the market growth. For instance, in March 2018, NovaQuest Capital Management L.L.C. acquired Viamet Pharmaceuticals (NC), Inc., which included the company's product candidate, VT-1161, which successfully completed Phase 2b clinical trials. The product is indicated for the treatment of recurrent vulvovaginal candidiasis and onychomycosis (fungal nail infection). Moreover, in 2014, NovaDigm Therapeutics acquired the rights to three Candida vaccine antigens from the Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, which significantly strengthened the company's candida vaccine pipeline.

Browse 40 Market Data Tables and 38 Figures spread through 178 Pages and in-depth TOC on “Candidiasis Market”- Global Forecast to 2026 by Drug Class (Azoles, Echinocandins, Polyenes, and Flucytosine), by Type (Candida Infections of the Mouth, Throat, and Esophagus, Vaginal Candidiasis, and Invasive/Systemic Candidiasis), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the global candidiasis market, click the link below: https://www.coherentmarketinsights.com/market-insight/candidiasis-market-229

Various market players and research institutes are focused on research and development activities to cater to unmet medical needs and provide more treatment options for patients with Candida auris and for patients having compromised immune systems. For instance, in August 2019, researchers from the Los Angeles Biomedical Research Institute (LA BioMed), a spinoff company of NovaDigm Therapeutics, started developing the vaccine-NDV-3A to prevent infections caused by C. auris in humans, after successfully immunizing and demonstrating its clinical efficacy in mice. Moreover, in 2017, the University Hospital of Cologne initiated a clinical trial to evaluate drug candidate SCY-078 in patients with fungal diseases that are refractory to or intolerant of standard antifungal treatment, in Europe.

Key Takeaways of the Global Candidiasis Market:                                   

• The global candidiasis market is expected to exhibit a CAGR of 4.6% over the forecast period, owing to factors such as increasing incidence of candidiasis infection and increasing number of mergers and acquisitions by market players
• Among drug class, the azoles segment held a major market share in 2017 as azoles are considered as the first-line agents in the treatment of various types of candidiasis such as esophageal and vaginal candidiasis
• Among type, the vaginal candidiasis segment held a major market share in 2017, owing to increasing research and development activities for product development in this segment
• Among route of administration, the oral segment held a higher market share in 2017, as several antifungal drugs used for the treatment and management of candidiasis are available in oral dosage form.
• Companies operating in the global candidiasis market include, Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc.